Contact In your country Home / Investors Investors Investor centre A global life sciences company Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease. Abcam’s shares are listed on the AIM market of the London Stock Exchange under the ABC ticker. Its ADSs are listed on the NASDAQ Global Market under the ABCM ticker. This area is dedicated to keeping shareholders and potential investors up to date with the share price, news and other relevant information. View share price & chart 2020 Annual Report A review of our performance and governance in 2020 Download 2020 Annual Report 2020 year in review Our social and financial value creation model Abcam is a global life sciences company providing highly validated antibodies and biological tools to the life scientist community. The success of our customers’ work, from basic research to translational science, diagnostics and therapeutic clinical programmes, relies on rigorous product quality, performance and reliability. Operating transparently and responsibly, we manage our business to generate attractive and sustainable long-term economic returns and value for all our stakeholders. Our business model Our markets Long-term industry forces across our markets remain attractive, with increases in research funding and capital investment supporting the growth of collaborative and global discovery networks. Read about our markets Our strategy Abcam’s goal is to create sustainable social and financial value, by helping accelerate the pace of discovery, and the translation of those discoveries into social impact. We are uniformly committed to responsibly pursuing that goal through our purpose and have a clear strategy to achieve this. View our strategy Our board and leadership We have a highly experienced Board and Senior Executive Team. The Board is responsible for the Group’s corporate governance, sets the Group’s strategy and policies, has overall responsibility for the oversight of risk and also monitors progress towards meeting its strategic objectives and annual plans. The Board discharges these responsibilities through a programme of meetings and also assesses whether or not, and to what extent, its obligations to the Company’s shareholders and other stakeholders are understood and met. This includes regular reviews of the Group’s financial performance and critical business issues. View board and leadership Latest financial news Abcam completes $340m strategic acquisition and expands kit capacity and capability 27 October 2021 Read more Interim results for the 6- and 12-month periods ended 30 June 2021 13 September 2021 Read more Abcam to acquire BioVision for $340 million 2 August 2021 Read more Reports and presentations View our latest results and presentations. Learn more Regulatory news Access the latest regulatory news Learn more Email subscription Stay up to date with investor email alerts. Subscribe Discovery Drive, Cambridge Biomedical Campus, Cambridge, CB2 0AX, UK +44 (0) 1223 696 000 VIEW PRODUCTS abcam.com abcam.co.jp abcam.cn About Innovation Partnering Sustainability Careers News & events Investors Contact Terms and conditions Privacy policy STATEMENTS Modern slavery statement Gender pay gap report Tax strategy © Abcam plc. all rights reserved. Abcam plc is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds. Website by FisherPaul By continuing to browse the site, you are agreeing to our use of cookies. Accept settings